THE EFFECT OF ADJUVANT THERAPY WITH OR WITHOUT TAMOXIFEN ON THE ENDOCRINE FUNCTION OF PATIENTS WITH BREAST-CANCER

被引：7

作者：

YASUMURA, T

AKAMI, T

MITSUO, M

OKA, T

NAITOH, K

YAMAMOTO, T

HONJYO, H

OKADA, H

机构：

[1] The Second Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, 602, Kawaramachi Hirokoji, Kamigyoku

[2] The Department of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Kyoto

来源：

JAPANESE JOURNAL OF SURGERY | 1990年 / 20卷 / 04期

关键词：

adjuvant therapy; breast cancer; chemotherapy; hormonal status; tamoxifen;

D O I：

10.1007/BF02470819

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

The ovarian and pituitary functions of 64 operable breast cancer patients undergoing adjuvant therapy with cytotoxic chemotherapy and/or tamoxifen were investigated. The post menopausal patients, divided into 3 treatment groups, one with tamoxifen alone, one with tamoxifen and chemotherapy and the other with chemotherapy alone had serum estradiol 17-β (E2) and progesterone levels lower than the evaluable limits. Although there was no significant difference in the level of estrone sulfate (E1-S) between these three groups, the level of lutainizing hormone (LH) and follicle stimulating hormone (FSH) in the patients treated with tamoxifen alone and tamoxifen and chemotherapy were significantly lower than those treated with chemotherapy alone. The decrease in gonadotropin levels induced by tamoxifen treatment was reversible as it appeared after the initiation of tamoxifen and recovered after its cessation. In the premenopausal patients, a group treated with tamoxifen and chemotherapy had significantly higher E1-S, E2 and progesterone levels and significantly lower gonadotropin levels than a group treated with chemotherapy alone or one treated with a cyclophosphamide regimen. These increases in the levels of estrogen and progesterone were also reversible, and induced by tamoxifen. Thus, adjuvant endocrinochemotherapy causes profound alteration in the hypothalamo-pituitary-ovarian axis and therefore, monitoring a variety of hormonal levels is thought to be necessary for assessing the consequences of adjuvant therapy in breast cancer patients, especially in premenopausal patients using tamoxifen. © 1990 The Japan Surgical Society.

引用

页码：369 / 375

页数：7

共 22 条

[1]

Fisher B., Redmond C., Brown A., Wolmark N., Wittleff J., Fisher E.R., Plotkin D., Bowman D., Sachs S., Wolter J., Frelick R., Desser R., LiCalzi N., Geggie P., Cambell T., Elias E.G., Prager D., Kootz P., Volk H., Dimitrov N., Gradner B., Lerner H., Shibata H., Treatment of primary breast cancer with chemotherapy and tamoxifen, New Engl J Med, 305, pp. 1-6, (1981)

[2]

Jordan V.C., Oestrogen and anti-oestrogen action: A hypothesis for the regulation of breast cancer cell replication, Endocrine therapy of breast cancer, Concept and Strategie, pp. 41-49, (1986)

[3]

Furr B.J.A., Jordan V.C., The pharmacology and clinical uses of tamoxifen, Pharmac Ther, 25, pp. 127-250, (1984)

[4]

Honjyo H., Kitawaki J., Itoh M., Yasuda J., Urabe M., Naitoh K., Yamamoto T., Okada H., Serum and urine estrone sulfate during the menstrual cycle, measured by a direct radioimmunoassay, and fate of exogeneous injected estrone sulfate, Hormone Research, 27, pp. 61-68, (1987)

[5]

Honjyo H., Aging of ovary and estrone sulfate, Adv Obstet Gynecol, 4, pp. 483-487, (1987)

[6]

Rose D.P., Davis T.E., Ovarian function in patients receiving adjuvant chemotherapy for breast cancer, Lancet, 1, pp. 1174-1176, (1977)

[7]

Dnistrian A.M., Schwartz M.K., Fracchia A.A., Kaufman R.J., Hakes T.B., Carrie V.E., Endocrine consequence of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients, Cancer, 51, pp. 803-807, (1983)

[8]

Helgason S., Wilkins N., Carlstrom K., Damber M.G., A comparative study of the estrogen effects of tamoxifen and 17β estradiol in postmenopausal women, J Clin Endocrinol Metabol, 54, pp. 404-407, (1982)

[9]

Delrio G., DePlacido S., Pegliarulo C., d'Istria M., Fasano S., Marinelli A., Citarella F., DeSio L., Contegiacomo A., Iaffaioli R.V., Petrilla G., Ricciardi I., Bianco A.R., Hypothalamic-pituitary-ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen, Tumori, 72, pp. 53-61, (1986)

[10]

Dnistrian A.M., Greenberg E.J., Dillon H.J., Hakes T.B., Fracchia A.A., Schwartz M.K., Chemohormonal therapy and endocrine function in breast cancer patients, Cancer, 56, pp. 63-70, (1985)

← 1 2 3 →